Effect of a Prodrug of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate on the Growth of Androgen-Independent Prostate Cancer In Vivo
- 26 June 2008
- journal article
- research article
- Published by Informa UK Limited in Nutrition and Cancer
- Vol. 60 (4), 483-491
- https://doi.org/10.1080/01635580801947674
Abstract
Epigallocatechin-3-gallate (EGCG) is the major and most potent polyphenol compound of green tea that has been shown to have anticancer effects against various types of cancers. In this study, in addition to the EGCG compound, a synthetic derivative, the peracetate of EGCG (EGCG-P), was used to investigate the inhibitory effects on growth of androgen-independent prostate cancer in vivo. The advantage of EGCG-P is that it may act as a prodrug, leading to higher bioavailability than EGCG itself. The aim of our study was to compare the differences between EGCG and EGCG-P on their inhibitory effect on androgen-independent prostate cancer, CWR22R, xenograft model in nude mice. The mice were administrated daily with solvent dimethyl sulfoxide, EGCG, and EGCG-P separately through intraperitoneal injection for 20 days. Tumor volume and body weight of nude mice were recorded daily. Serum prostate-specific antigen (PSA) levels were also measured before and after the treatment. The effects of both EGCG and EGCG-P on tumor cell proliferation were assessed by immunohistochemical (IHC) method using antibodies against Ki-67 and proliferating cell nuclear antigen. The apoptotic effect was evaluated by IHC against B-cell non-Hodgkin lymphoma-2 and terminal deoxynucleotidyl transferase dUTP nick-end labeling assay by in situ apoptosis detection kit. Moreover, the potential suppression of angiogenesis by EGCG and EGCG-P on prostate cancer was examined by IHC against CD31. Our results revealed that treatment of EGCG and EGCG-P compounds suppressed the growth of CWR22R xenografts without causing any detectable side effects in nude mice. The suppression of growth of the tumor was correlated with the decrease of serum PSA level together with the reduction in tumor angiogenesis and an increase in apoptosis on prostate cancer cells. The results showed that treatment of EGCG and EGCG-P inhibited tumor growth and angiogenesis while promoting apoptosis of the prostate cancer cells in vivo. Our results suggest that EGCG-P may be a more stable and useful compound for increasing the therapeutic anticancer effects in androgen-independent prostate cancer.Keywords
This publication has 30 references indexed in Scilit:
- Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate CancerOncology, 2005
- Advances in Prostate Cancer Chemotherapy: A New Era BeginsCA: A Cancer Journal for Clinicians, 2005
- Chemoprevention of prostate cancerCritical Reviews in Oncology/Hematology, 2005
- Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cellsInternational Journal of Cancer, 2004
- A case‐control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese dietCancer Science, 2004
- Green tea and tea polyphenols in cancer preventionFrontiers in Bioscience-Landmark, 2004
- Protective effect of green tea against prostate cancer: A case‐control study in southeast ChinaInternational Journal of Cancer, 2003
- Molecular Targets for Green Tea in Prostate Cancer PreventionJournal of Nutrition, 2003
- Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdomSurgical Oncology, 2002
- Induction of apoptosis in prostate cancer cell lines by the green tea component, (−)-epigallocatechin-3-gallateCancer Letters, 1998